Tools & Wizards About Us
bmccorner.com screenshot

Report Summary

  • 28

    Performance

    Renders faster than
    47% of other websites

  • 82

    Accessibility

    Visual factors better than
    that of 52% of websites

  • 83

    Best Practices

    More advanced features
    available than in
    55% of websites

  • 85

    SEO

    Google-friendlier than
    55% of websites

bmccorner.com

BioTech Health X • BioTech News & BioTech Stock Analysis

Page Load Speed

3.5 sec in total

First Response

33 ms

Resources Loaded

1.8 sec

Page Rendered

1.6 sec

bmccorner.com screenshot

About Website

Click here to check amazing Bmccorner content for India. Otherwise, check out these important facts you probably never knew about bmccorner.com

BioTech News, Life Sciences Health & BioTech Stock Market. Biotechnology Companies Insights, Pharmaceuticals, Drug Development, Phase Trials & Therapeutics.

Visit bmccorner.com

Key Findings

We analyzed Bmccorner.com page load time and found that the first response time was 33 ms and then it took 3.4 sec to load all DOM resources and completely render a web page. This is a poor result, as 60% of websites can load faster.

Performance Metrics

bmccorner.com performance score

28

Measured Metrics

name

value

score

weighting

FCP (First Contentful Paint)

Value3.2 s

43/100

10%

LCP (Largest Contentful Paint)

Value9.5 s

0/100

25%

SI (Speed Index)

Value6.7 s

36/100

10%

TBT (Total Blocking Time)

Value1,530 ms

13/100

30%

CLS (Cumulative Layout Shift)

Value0.003

100/100

15%

TTI (Time to Interactive)

Value15.1 s

7/100

10%

Network Requests Diagram

bmccorner.com

33 ms

biotechhealthx.com

363 ms

powerkit.css

73 ms

style.min.css

133 ms

public-powerkit-author-box.css

194 ms

Our browser made a total of 99 requests to load all elements on the main page. We found that 1% of them (1 request) were addressed to the original Bmccorner.com, 84% (83 requests) were made to Biotechhealthx.com and 2% (2 requests) were made to Googletagmanager.com. The less responsive or slowest element that took the longest time to load (829 ms) relates to the external source Biotechhealthx.com.

Page Optimization Overview & Recommendations

Page size can be reduced by 355.7 kB (24%)

Content Size

1.5 MB

After Optimization

1.1 MB

  • HTML
  • Images
  • JavaScript
  • CSS

In fact, the total size of Bmccorner.com main page is 1.5 MB. This result falls beyond the top 1M of websites and identifies a large and not optimized web page that may take ages to load. 75% of websites need less resources to load and that’s why Accessify’s recommendations for optimization and resource minification can be helpful for this project. Images take 606.5 kB which makes up the majority of the site volume.

HTML Optimization

-89%

Potential reduce by 341.6 kB

  • Original 384.6 kB
  • After minification 357.3 kB
  • After compression 43.0 kB

HTML content can be minified and compressed by a website’s server. The most efficient way is to compress content using GZIP which reduces data amount travelling through the network between server and browser. HTML code on this page is well minified. It is highly recommended that content of this web page should be compressed using GZIP, as it can save up to 341.6 kB or 89% of the original size.

Image Optimization

-0%

Potential reduce by 1.7 kB

  • Original 606.5 kB
  • After minification 604.8 kB

Image size optimization can help to speed up a website loading time. The chart above shows the difference between the size before and after optimization. Bmccorner images are well optimized though.

JavaScript Optimization

-1%

Potential reduce by 5.0 kB

  • Original 415.1 kB
  • After minification 413.6 kB
  • After compression 410.1 kB

It’s better to minify JavaScript in order to improve website performance. The diagram shows the current total size of all JavaScript files against the prospective JavaScript size after its minification and compression. This website has mostly compressed JavaScripts.

CSS Optimization

-9%

Potential reduce by 7.3 kB

  • Original 83.8 kB
  • After minification 83.5 kB
  • After compression 76.5 kB

CSS files minification is very important to reduce a web page rendering time. The faster CSS files can load, the earlier a page can be rendered. Bmccorner.com has all CSS files already compressed.

Requests Breakdown

Number of requests can be reduced by 49 (53%)

Requests Now

93

After Optimization

44

  • AJAX
  • Images
  • JavaScript
  • CSS

The browser has sent 93 CSS, Javascripts, AJAX and image requests in order to completely render the main page of Bmccorner. We recommend that multiple CSS and JavaScript files should be merged into one by each type, as it can help reduce assets requests from 29 to 1 for JavaScripts and from 22 to 1 for CSS and as a result speed up the page load time.

Network Requests Diagram

bmccorner.com

bmccorner.com

33 ms

biotechhealthx.com

biotechhealthx.com

363 ms

powerkit.css

powerkit.css

73 ms

style.min.css

style.min.css

133 ms

public-powerkit-author-box.css

public-powerkit-author-box.css

194 ms

public-powerkit-basic-elements.css

public-powerkit-basic-elements.css

195 ms

public-powerkit-content-formatting.css

public-powerkit-content-formatting.css

178 ms

public-powerkit-contributors.css

public-powerkit-contributors.css

181 ms

public-powerkit-facebook.css

public-powerkit-facebook.css

196 ms

public-powerkit-featured-categories.css

public-powerkit-featured-categories.css

197 ms

public-powerkit-inline-posts.css

public-powerkit-inline-posts.css

231 ms

public-powerkit-instagram.css

public-powerkit-instagram.css

237 ms

public-powerkit-justified-gallery.css

public-powerkit-justified-gallery.css

246 ms

glightbox.min.css

glightbox.min.css

255 ms

public-powerkit-lightbox.css

public-powerkit-lightbox.css

257 ms

public-powerkit-opt-in-forms.css

public-powerkit-opt-in-forms.css

258 ms

public-powerkit-pinterest.css

public-powerkit-pinterest.css

283 ms

public-powerkit-share-buttons.css

public-powerkit-share-buttons.css

292 ms

public-powerkit-slider-gallery.css

public-powerkit-slider-gallery.css

300 ms

public-powerkit-social-links.css

public-powerkit-social-links.css

313 ms

public-powerkit-twitter.css

public-powerkit-twitter.css

319 ms

public-powerkit-widget-about.css

public-powerkit-widget-about.css

320 ms

style.css

style.css

397 ms

style.css

style.css

346 ms

jquery.min.js

jquery.min.js

419 ms

jquery-migrate.min.js

jquery-migrate.min.js

370 ms

js

js

94 ms

adsbygoogle.js

adsbygoogle.js

70 ms

sdk.js

sdk.js

39 ms

index.js

index.js

365 ms

index.js

index.js

364 ms

public-powerkit-basic-elements.js

public-powerkit-basic-elements.js

413 ms

jquery.justifiedGallery.min.js

jquery.justifiedGallery.min.js

662 ms

public-powerkit-justified-gallery.js

public-powerkit-justified-gallery.js

659 ms

imagesloaded.min.js

imagesloaded.min.js

660 ms

glightbox.min.js

glightbox.min.js

829 ms

public-powerkit-lightbox.js

public-powerkit-lightbox.js

828 ms

public-powerkit-opt-in-forms.js

public-powerkit-opt-in-forms.js

827 ms

pinit.js

pinit.js

36 ms

public-powerkit-pin-it.js

public-powerkit-pin-it.js

827 ms

public-powerkit-scroll-to-top.js

public-powerkit-scroll-to-top.js

828 ms

public-powerkit-share-buttons.js

public-powerkit-share-buttons.js

827 ms

flickity.pkgd.min.js

flickity.pkgd.min.js

778 ms

public-powerkit-slider-gallery.js

public-powerkit-slider-gallery.js

717 ms

colcade.js

colcade.js

672 ms

ofi.min.js

ofi.min.js

668 ms

scripts.js

scripts.js

657 ms

gtm.js

gtm.js

400 ms

7b4da75be238ac49072fa8711.js

7b4da75be238ac49072fa8711.js

414 ms

7ff03d00cc6a6864c9671603633f131c

7ff03d00cc6a6864c9671603633f131c

388 ms

BioTech-Health-X-Menu-Logo.png

BioTech-Health-X-Menu-Logo.png

334 ms

Vera-Therapeutics-Atacicept-Shows-Promising-Results-in-Phase-2b-ORIGIN-Trial-for-IgA-Nephropathy-550x330.jpg

Vera-Therapeutics-Atacicept-Shows-Promising-Results-in-Phase-2b-ORIGIN-Trial-for-IgA-Nephropathy-550x330.jpg

436 ms

Ozempic-Shows-Lower-Risk-of-Kidney-and-Heart-Complications-in-Diabetic-Patients-255x150.jpg

Ozempic-Shows-Lower-Risk-of-Kidney-and-Heart-Complications-in-Diabetic-Patients-255x150.jpg

436 ms

Eli-Lilly-Announces-Historic-5.3-Billion-Investment-to-Expand-Indiana-Manufacturing-for-Diabetes-and-Weight-Loss-Drugs-255x150.jpg

Eli-Lilly-Announces-Historic-5.3-Billion-Investment-to-Expand-Indiana-Manufacturing-for-Diabetes-and-Weight-Loss-Drugs-255x150.jpg

434 ms

Guardant-Health-Shield-Blood-Test-for-Colorectal-Cancer-Receives-FDA-Advisory-Panel-Endorsement-255x150.jpg

Guardant-Health-Shield-Blood-Test-for-Colorectal-Cancer-Receives-FDA-Advisory-Panel-Endorsement-255x150.jpg

434 ms

Coherus-Presents-Promising-Phase-I-Results-for-Anti-CCR8-Antibody-CHS-114-at-ASCO-2024-255x150.jpg

Coherus-Presents-Promising-Phase-I-Results-for-Anti-CCR8-Antibody-CHS-114-at-ASCO-2024-255x150.jpg

436 ms

Vera-Therapeutics-Atacicept-Shows-Promising-Results-in-Phase-2b-ORIGIN-Trial-for-IgA-Nephropathy-380x220.jpg

Vera-Therapeutics-Atacicept-Shows-Promising-Results-in-Phase-2b-ORIGIN-Trial-for-IgA-Nephropathy-380x220.jpg

433 ms

Ozempic-Shows-Lower-Risk-of-Kidney-and-Heart-Complications-in-Diabetic-Patients-380x220.jpg

Ozempic-Shows-Lower-Risk-of-Kidney-and-Heart-Complications-in-Diabetic-Patients-380x220.jpg

499 ms

Eli-Lilly-Announces-Historic-5.3-Billion-Investment-to-Expand-Indiana-Manufacturing-for-Diabetes-and-Weight-Loss-Drugs-380x220.jpg

Eli-Lilly-Announces-Historic-5.3-Billion-Investment-to-Expand-Indiana-Manufacturing-for-Diabetes-and-Weight-Loss-Drugs-380x220.jpg

499 ms

Guardant-Health-Shield-Blood-Test-for-Colorectal-Cancer-Receives-FDA-Advisory-Panel-Endorsement-380x220.jpg

Guardant-Health-Shield-Blood-Test-for-Colorectal-Cancer-Receives-FDA-Advisory-Panel-Endorsement-380x220.jpg

501 ms

Coherus-Presents-Promising-Phase-I-Results-for-Anti-CCR8-Antibody-CHS-114-at-ASCO-2024-380x220.jpg

Coherus-Presents-Promising-Phase-I-Results-for-Anti-CCR8-Antibody-CHS-114-at-ASCO-2024-380x220.jpg

502 ms

Vera-Therapeutics-Atacicept-Shows-Promising-Results-in-Phase-2b-ORIGIN-Trial-for-IgA-Nephropathy-380x253.jpg

Vera-Therapeutics-Atacicept-Shows-Promising-Results-in-Phase-2b-ORIGIN-Trial-for-IgA-Nephropathy-380x253.jpg

503 ms

Ozempic-Shows-Lower-Risk-of-Kidney-and-Heart-Complications-in-Diabetic-Patients-380x253.jpg

Ozempic-Shows-Lower-Risk-of-Kidney-and-Heart-Complications-in-Diabetic-Patients-380x253.jpg

503 ms

Eli-Lilly-Announces-Historic-5.3-Billion-Investment-to-Expand-Indiana-Manufacturing-for-Diabetes-and-Weight-Loss-Drugs-380x214.jpg

Eli-Lilly-Announces-Historic-5.3-Billion-Investment-to-Expand-Indiana-Manufacturing-for-Diabetes-and-Weight-Loss-Drugs-380x214.jpg

593 ms

Guardant-Health-Shield-Blood-Test-for-Colorectal-Cancer-Receives-FDA-Advisory-Panel-Endorsement-380x167.jpg

Guardant-Health-Shield-Blood-Test-for-Colorectal-Cancer-Receives-FDA-Advisory-Panel-Endorsement-380x167.jpg

594 ms

Coherus-Presents-Promising-Phase-I-Results-for-Anti-CCR8-Antibody-CHS-114-at-ASCO-2024-380x254.jpg

Coherus-Presents-Promising-Phase-I-Results-for-Anti-CCR8-Antibody-CHS-114-at-ASCO-2024-380x254.jpg

594 ms

Myriad-Genetics-Unveils-Groundbreaking-Cancer-Care-Innovations-at-ASCO-2024-1-380x254.jpg

Myriad-Genetics-Unveils-Groundbreaking-Cancer-Care-Innovations-at-ASCO-2024-1-380x254.jpg

594 ms

Biogen-Expands-Immunology-Portfolio-with-Strategic-Acquisition-380x195.jpg

Biogen-Expands-Immunology-Portfolio-with-Strategic-Acquisition-380x195.jpg

592 ms

Takeda-Inks-Licensing-Deal-with-Degron-Therapeutics-for-Molecular-Glue-Degraders-380x266.jpg

Takeda-Inks-Licensing-Deal-with-Degron-Therapeutics-for-Molecular-Glue-Degraders-380x266.jpg

593 ms

FDA-Approves-Biosimilars-Yesafili-and-Opuviz-Opening-New-Avenues-for-Affordable-Eye-Treatments-380x253.jpg

FDA-Approves-Biosimilars-Yesafili-and-Opuviz-Opening-New-Avenues-for-Affordable-Eye-Treatments-380x253.jpg

627 ms

Oak-Hill-Bio-and-Chiesi-Resume-Phase-2b-Clinical-Study-for-OHB-607-to-Treat-Bronchopulmonary-Dysplasia-380x214.jpg

Oak-Hill-Bio-and-Chiesi-Resume-Phase-2b-Clinical-Study-for-OHB-607-to-Treat-Bronchopulmonary-Dysplasia-380x214.jpg

627 ms

7ff03d00cc6a6864c9671603633f131c

7ff03d00cc6a6864c9671603633f131c

331 ms

show_ads_impl.js

show_ads_impl.js

236 ms

FDA-Delays-Moderna-RSV-Vaccine-Decision-380x253.jpg

FDA-Delays-Moderna-RSV-Vaccine-Decision-380x253.jpg

483 ms

Novavax-Announces-Robust-First-Quarter-2024-Results-and-Strategic-Partnerships-380x253.jpg

Novavax-Announces-Robust-First-Quarter-2024-Results-and-Strategic-Partnerships-380x253.jpg

482 ms

Novavax-and-Sanofi-Forge-1-2-Billion-Alliance-to-Boost-COVID-and-Flu-Vaccine-Efforts-380x285.jpg

Novavax-and-Sanofi-Forge-1-2-Billion-Alliance-to-Boost-COVID-and-Flu-Vaccine-Efforts-380x285.jpg

480 ms

CEL-SCI-Advances-in-Cancer-Treatment-with-FDA-Approval-for-Confirmatory-Multikine-Study-380x253.jpg

CEL-SCI-Advances-in-Cancer-Treatment-with-FDA-Approval-for-Confirmatory-Multikine-Study-380x253.jpg

314 ms

BIOQUAL-Biotechnology-380x253.jpg

BIOQUAL-Biotechnology-380x253.jpg

344 ms

Petros-Pharmaceuticals-380x214.jpg

Petros-Pharmaceuticals-380x214.jpg

343 ms

RAPT-Therapeutics-Announces-Promising-Phase-2-Trial-Results-for-Tivumecirnon-380x244.jpg

RAPT-Therapeutics-Announces-Promising-Phase-2-Trial-Results-for-Tivumecirnon-380x244.jpg

340 ms

cigna-headquarters-380x253.jpeg

cigna-headquarters-380x253.jpeg

344 ms

Vera-Therapeutics-Atacicept-Shows-Promising-Results-in-Phase-2b-ORIGIN-Trial-for-IgA-Nephropathy-110x110.jpg

Vera-Therapeutics-Atacicept-Shows-Promising-Results-in-Phase-2b-ORIGIN-Trial-for-IgA-Nephropathy-110x110.jpg

342 ms

Ozempic-Shows-Lower-Risk-of-Kidney-and-Heart-Complications-in-Diabetic-Patients-110x110.jpg

Ozempic-Shows-Lower-Risk-of-Kidney-and-Heart-Complications-in-Diabetic-Patients-110x110.jpg

339 ms

icons.ttf

icons.ttf

388 ms

powerkit-icons.woff

powerkit-icons.woff

389 ms

now-alt-700.woff

now-alt-700.woff

384 ms

Eli-Lilly-Announces-Historic-5.3-Billion-Investment-to-Expand-Indiana-Manufacturing-for-Diabetes-and-Weight-Loss-Drugs-110x110.jpg

Eli-Lilly-Announces-Historic-5.3-Billion-Investment-to-Expand-Indiana-Manufacturing-for-Diabetes-and-Weight-Loss-Drugs-110x110.jpg

380 ms

Guardant-Health-Shield-Blood-Test-for-Colorectal-Cancer-Receives-FDA-Advisory-Panel-Endorsement-110x110.jpg

Guardant-Health-Shield-Blood-Test-for-Colorectal-Cancer-Receives-FDA-Advisory-Panel-Endorsement-110x110.jpg

384 ms

Coherus-Presents-Promising-Phase-I-Results-for-Anti-CCR8-Antibody-CHS-114-at-ASCO-2024-110x110.jpg

Coherus-Presents-Promising-Phase-I-Results-for-Anti-CCR8-Antibody-CHS-114-at-ASCO-2024-110x110.jpg

380 ms

sdk.js

sdk.js

54 ms

embed.js

embed.js

117 ms

hiv-virus-medical-concept-human-immunodeficiency-2023-04-03-21-45-17-utc-300x180.jpg

hiv-virus-medical-concept-human-immunodeficiency-2023-04-03-21-45-17-utc-300x180.jpg

379 ms

Immunis-Inc.-Advances-as-Finalist-in-Octane-High-Tech-Awards-for-Pioneering-Work-in-Cellular-Secretome-Therapies-300x180.jpg

Immunis-Inc.-Advances-as-Finalist-in-Octane-High-Tech-Awards-for-Pioneering-Work-in-Cellular-Secretome-Therapies-300x180.jpg

377 ms

CEL-SCI-Multikine-Phase-3-Data-Highlighted-at-ESMO-2022-300x180.jpg

CEL-SCI-Multikine-Phase-3-Data-Highlighted-at-ESMO-2022-300x180.jpg

378 ms

pinit_main.js

pinit_main.js

63 ms

zrt_lookup.html

zrt_lookup.html

154 ms

ads

ads

106 ms

96 ms

powerkit-icons.woff

powerkit-icons.woff

58 ms

Accessibility Review

bmccorner.com accessibility score

82

Accessibility Issues

ARIA

These are opportunities to improve the usage of ARIA in your application which may enhance the experience for users of assistive technology, like a screen reader.

Impact

Issue

High

[aria-hidden="true"] elements contain focusable descendents

Names and labels

These are opportunities to improve the semantics of the controls in your application. This may enhance the experience for users of assistive technology, like a screen reader.

Impact

Issue

High

Buttons do not have an accessible name

High

<frame> or <iframe> elements do not have a title

High

Links do not have a discernible name

Contrast

These are opportunities to improve the legibility of your content.

Impact

Issue

High

Background and foreground colors do not have a sufficient contrast ratio.

Navigation

These are opportunities to improve keyboard navigation in your application.

Impact

Issue

High

Heading elements are not in a sequentially-descending order

Best Practices

bmccorner.com best practices score

83

Areas of Improvement

Trust and Safety

Impact

Issue

High

Does not use HTTPS

High

Includes front-end JavaScript libraries with known security vulnerabilities

Low

Ensure CSP is effective against XSS attacks

General

Impact

Issue

Low

Detected JavaScript libraries

High

Page has valid source maps

SEO Factors

bmccorner.com SEO score

85

Search Engine Optimization Advices

Content Best Practices

Format your HTML in a way that enables crawlers to better understand your app’s content.

Impact

Issue

High

Links do not have descriptive text

Crawling and Indexing

To appear in search results, crawlers need access to your app.

Impact

Issue

High

Links are not crawlable

Mobile Friendly

Make sure your pages are mobile friendly so users don’t have to pinch or zoom in order to read the content pages. [Learn more](https://developers.google.com/search/mobile-sites/).

Impact

Issue

High

Document uses legible font sizes

High

Tap targets are not sized appropriately

Language and Encoding

  • Language Detected

    EN

  • Language Claimed

    EN

  • Encoding

    UTF-8

Language claimed in HTML meta tag should match the language actually used on the web page. Otherwise Bmccorner.com can be misinterpreted by Google and other search engines. Our service has detected that English is used on the page, and it matches the claimed language. Our system also found out that Bmccorner.com main page’s claimed encoding is utf-8. Use of this encoding format is the best practice as the main page visitors from all over the world won’t have any issues with symbol transcription.

Social Sharing Optimization

bmccorner.com

Open Graph data is detected on the main page of Bmccorner. This is the best way to make the web page social media friendly. Here is how it looks like on Facebook: